AstraZeneca’s investigational antibody for chronic obstructive pulmonary disease has succeeded in two late-stage studies, despite having previously failed in a mid-stage trial. And, unexpectedly, the company revealed Friday the drug yielded positive data in a …
#AAD26: Biogen declares Phase 2 lupus success for anti-BDCA2 antibody
Biogen trumpeted new Phase 2 lupus data on Saturday for a program it hopes will become a pillar of its immunology pipeline. The drug litifilimab



